Sernova Biotherapeutics Inc · TSX:SVA
Sernova Biotherapeutics — Sernova — Investor Presentation (January 2022)
33 slides from Sernova Biotherapeutics's investor presentation, January 2022

Slide 1: Corporate Investor Deck
Corporate Investor Deck January, 2022

Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward- looking statements in this presentation are statements that are not historical facts and are generally, but not always, identified by the words “expect

Slide 3: Sernova is a clinical-stage regenerative medicine company
Sernova Corp. is a Regenerative Medicine clinical- stage company developing therapeutic products for chronic debilitating diseases. The Company’s proprietary Cell Pouch System™ consists of an implantable device containing immuno- protected therapeutic cells capable of sustainably producing missing t

Slide 4: Platform Approach: Finding Functional Cure for Chronic Diseases
Platform Approach: Finding Functional Cure for Chronic Diseases Integrated Regenerative Medicine Solution for Treatment of Chronic Diseases Immune Cell Pouch Protection Proprietary implantable Cell Pouch Immune 2nd generation devices utilize medical device that provides vascularized environment for

Slide 5: Investment Highlights – Cell Pouch System
Investment Highlights – Cell Pouch System • Proprietary implantable device containing therapeutic cells for organ-like environment Proprietary Cell • Once implanted, is naturally vascularized allowing self-sustaining cell survival for years Pouch System™ • 2nd generation allows for immuno-protection

Slide 6: Cell Pouch Containing Therapeutic Cells
Cell Pouch Containing Therapeutic Cells Biologically compatible delivery process – allows natural vascularization Proprietary Cell Pouch is placed Therapeutics cells are transplanted Therapeutic cells are responsive to deep under the skin, allowing for directly into the vascularized tissue endogenou

Slide 7: Cell Pouch has Overcome Limitations of Previous Attempts
Cell Pouch has Overcome Limitations of Previous Attempts Sernova has created an organ-like environment with the goal of providing ‘functional cure’ Human donor cells Tissue Vascularizes Stem cell-derived islet cells No Fibrosis Sernova Scalable Cell Pouch Natural cell environment Biocompatible Cell

Slide 8: Pipeline – Life Cycle Iterations and Multiple Indications
Pipeline – Life Cycle Iterations and Multiple Indications Therapeutic Immune Market Approval Product Candidate Cell Source Protection Indication Pre-Clinical Phase 1/2 Phase 3 Application Human donor islet Cell Pouch System Immunosuppressives cells Human donor islet Local immune 2nd Gen System Type

Slide 9: Cell Pouch System Clinical Program
Cell Pouch System Clinical Program Moving towards a ‘functional cure’ for T1D

Slide 10: Diabetes: Global Disease = Global Market
GLOBAL DISEASE = GLOBAL MARKET DIABETES Diabetes is one of the module prevalent diseases pervasive medical problems, impacting society and everyday quality of life today. 463 million people are affected worldwide with Diabetes; another estimated 179 million people have it without knowing it. By 2045

Slide 11: Lead Diabetes Indication: Hypoglycemia Unawareness
LEAD DIABETES INDICATION Hypoglycemia - Unawareness Among Type 1 Diabetics Brittle diabetes – most critical unmet need in T1D Affects 15% of T1D patients (~240k patients in the US) Clinically defined as complication of diabetes in which patient in unaware of a deep drop in blood sugar Patients do no

Slide 12: Phase I/II Study Design
Phase I/II Study Design 7 Patients with Type 1 Diabetes (T1D) Study Overview Company sponsored open label single-arm, single-center study Study Enroll 7 insulin dependent T1D patients Human donor islets transplanted into Cell Pouch after implantation Design Standard of care for immunosuppres

Slide 13: Phase I/II Study Design (N = 7)
Phase I/II Study Design (N = 7) Primary Study Long-term Follow-up and Tracking Baseline 1 MO +1 MO +6-12 MO +6-12 MO Ongoing Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 13

Slide 14: Case Study: Longest Patient Insulin Independent for >20 Months
Case Study: Longest Patient Insulin Independent for >20 Months Dr. Witkowski presents patient data at international conferences BEFORE ISLET TRANSPLANT Post 1st ISLET TRANSPLANT* Post TOP-UP INFUSION** (baseline) (32 months after baseline) *Marginal Islet Dose **Marginal Islet Dose intraportal top u

Slide 15: Patient #1 – Impact Statement
Patient #1 – Impact Statement After completing the safety, tolerability and efficacy study of Sernova's Cell Pouch for clinical islet transplantation and as the first transplant candidate, I can easily state how absolutely wonderful life is to be free of always thinking of how to manage my diabetes.

Slide 16: T1D Phase 1/2 Findings Presented To-Date
T1D Phase 1/2 Findings Presented To-Date The Sernova Cell Pouch System is the first regenerative medicine to demonstrate a subcutaneous transplanted device to achieve persistent islet cell graft function in T1D patients Safety Assessments1: • 6 patients now successfully implanted and transplanted wi

Slide 17: Cell Pouch Diabetes Program – Progress & Upcoming Events
Cell Pouch Diabetes Program – Progress & Upcoming Events Internal and External Advancement of Development and Commercialization Strategy Current Phase 1/2 Clinical Study • Completion of study enrollment; completion of patient follow-up and study report • Additional top-line data expected in 2022 Exp

Slide 18: 2nd Generation Enhancements
2nd Generation Enhancements Immune Protection • Conformal Coating • Gene Editing

Slide 19: Conformal Coating Technology for Cell Pouch Immune Protection
Conformal Coating Technology for Cell Pouch Immune Protection Potential to eliminate the need for immunosuppressives Conformal Coating University of Miami / Sernova Collaboration Plan Conformal Coating Technology developed and optimized with >12 years of research Polymer characterization studies at

Slide 20: Conformal Coating + Cell Pouch: Summary of Key Findings
Conformal Coating + Cell Pouch: Summary of Key Findings Conformal Cell Pouch + Coating with Immuno-protection Summary Cells Cells Safety in non-human primates • Due to its ‘shrink wrap’ proximity to the cells, the volume of cells for transplantation into the Cell Pouch is unaffected Efficacy wit

Slide 21: Gene Editing for Stem Cells in Cell Pouch - Immune Protection
Gene Editing for Stem Cells in Cell Pouch - Immune Protection AgeX technology for potential off-the-shelf islet cell transplantation product • AgeX collaboration ongoing to confirm the potential of Sernova’s pluripotent stem cell-derived pancreatic islet beta cells engineered with AgeX’s UniverCyte

Slide 22: Additional Pipeline: Thyroid Diseases, Hemophilia A
Additional Pipeline Thyroid Diseases Hemophilia A

Slide 23: Cell Pouch System Thyroid Program
Cell Pouch System Thyroid Program Therapeutic Benefits & Estimated Market ➡ 150,000 thyroidectomies performed annually just in the US Estimated $ ➡ $2.2B market opportunity Market Size ➡ Potential near term revenue with patient own tissue ➡ Stem cell-derived technology for treatment of broad populat

Slide 24: Treatment of Thyroid
Thyroid Disease Indication To develop a therapeutic product for patients undertaking total or near total thyroidectomy and prevent post-operative hypothyroidism symptoms This includes auto-transplantation of patients’ own healthy thyroid Candidates for Sernova’s tissues within the Sernova Cell Pouch

Slide 25: Thyroid Disease Indication
Thyroid Disease Indication Preclinical Safety and Efficacy Study Confidential Procedure: Results: Human Thyroglobulin Histology Assessments (hTG) IF-20x Human Thyroid Tissue hTG Blood Measurement Human Thyroperoxidase 21 2 0 IF-20x (hTPO) 5 h u m a n T h y r o g lo b u lin ( µ g /L ) IF-20x 100 80 6

Slide 26: Cell Pouch System Rare Disease Program
Cell Pouch System Rare Disease Program Hemophilia A Therapeutic Benefits & Estimated Market Estimated ➡ 20,000 patients across North America and EU Market Size $ ➡ $10B orphan indication ➡ First generation • AUTOGRAFT: Patient’s own blood outgrowth endothelial cells (BOEC) are isolated, expanded and

Slide 27: Hemophilia A Indication
Hemophilia A Indication Preclinical Safety & Efficacy of Hemophilia Cell Therapy in the Cell Pouch Confirmed Release-tested HLA-ABC BOECs FVIII DAPI Human stained (red) 40x Cell Pouch Transplanted with Cells Human corrected Human factor VIII- BOECs transplanted corrected blood 40× into the Cell Pouc

Slide 28: Manufacturing and IP Milestones
Manufacturing and IP Milestones

Slide 29: Cell Pouch cGMP Manufacturing
Cell Pouch cGMP Manufacturing cGMP manufacture of the Cell Pouch in multiple sizes by US CMO in a Class VII Clean Room Product and process development is conducted in accordance with CMO’s Quality System ISO 13485 EU Medical Devices regular MDR 2017/745 US FDA Quality System Regulations (QSR) 32 CFR

Slide 30: International Patent Portfolio
International Patent Portfolio Broad Geographic Coverage Sernova has an international patent and patent applications portfolio in multiple patent families for broad applications and continued expansion • Composition and use of medical devices for delivery and cell transplantation • Glucose responsiv

Slide 31: Sernova Next Steps / Upcoming Milestones
Sernova Next Steps / Upcoming Milestones Action Plan 01 Cell Pouch System Platform Technology Develop licensed / acquired local immune-protection technologies for therapeutic cells Prepare local immune-protected diabetes islets and stem cell technology in preparation for First-in-Human (FIH) stu

Slide 32: Sernova Shares Information
Sernova Shares Information TSX VENTURE OTC QB FRANKFURT / EXCHANGE EXCHANGE XETRA SVA SEOVF PSH $1.94 US$1.51 €1.30 Shares Market Cap $505M Fully Outstanding Diluted Strong Cash ~322M ~261M Position $27M In millions except share price Share Prices and Market Cap as of December 29, 2021

Slide 33: Head Office, Business Development, Investor Relations
Head Office 700 Collip Circle, Ste 114 London, ON, Canada N6G 4X8 Tel: 1.877.299.4603 Tel: 1.519.858.5184 Fax: 1.519.858.5099 investorrelations@sernova.com Business Development Investor Relations Dr. Philip Toleikis Christopher Barnes 1.519.858.5184 VP, Investor Relations philip.toleikis@sernova.com
Source: Internet Archive copy of sernova.com
More decks from Sernova Biotherapeutics Inc
Merger or Acquisition (2026)16 slides · 2026
Investor Presentation (February 2025)24 slides · February 2025
Investor Presentation (December 2024)31 slides · December 2024
Investor Presentation (September 2024)21 slides · Sep 12, 2024
Investor Presentation (March 2024)32 slides · March 2024
Sernova — Investor Presentation (September 2023)27 slides · September 2023